Table 1. Description of the study population by eligibility for obesity medication: analysis accounting for complex survey design.

	Eligibility for obesity medication
	No (n = 193,502)	Yes (n = 66,629)	p-value *
Sex			<0.001
Males	90,809 (77.1%)	22,986 (22.9%)
Females	102,693 (68.3%)	43,643 (31.7%)
Age (categories)			<0.001
< 30 years	61,815 (85.7%)	11,474 (14.3%)
30 – 39 years	53,138 (73.4%)	19,456 (26.6%)
40 – 49 years	29,606 (66.7%)	13,943 (33.3%)
50 – 59 years	19,591 (63.0%)	10,109 (37.0%)
60 – 69 years	14,652 (62.9%)	7,216 (37.1%)
70+ years	14,700 (71.8%)	4,431 (28.2%)
Education level			<0.001
< 7 years	52,089 (71.9%)	17,160 (28.1%)
7 – 11 years	77,917 (71.4%)	27,502 (28.6%)
12+ years	54,513 (73.1%)	19,918 (26.9%)
Socioeconomic level			<0.001
Very low	45,722 (84.2%)	8,459 (15.8%)
Low	41,694 (81.7%)	9,038 (18.3%)
Middle	35,238 (69.0%)	15,577 (31.0%)
High	33,500 (65.9%)	16,934 (34.1%)
Very high	37,348 (69.0%)	16,621 (31.0%)
Geographic area			<0.001
Urban	117,825 (68.8%)	51,446 (31.2%)
Rural	75,677 (83.4%)	15,183 (16.6%)
Study year			<0.001
2014	19,583 (75.6%)	5,733 (24.4%)
2015	23,753 (75.4%)	6,985 (24.6%)
2016	22,767 (74.9%)	6,993 (25.1%)
2017	23,254 (73.4%)	7,421 (26.6%)
2018	23,607 (71.6%)	8,389 (28.4%)
2019	23,003 (72.1%)	8,040 (27.9%)
2020	14,860 (69.9%)	5,911 (30.1%)
2021	20,833 (68.3%)	8,575 (31.7%)
2022	21,842 (69.2%)	8,582 (30.8%)

Proportions are weighted according to complex survey design.

* P-value was estimated utilizing the Chi-squared test with the Rao-Scott second-order correction.